Key Catalyst Next Week for Actinium Pharma (ATNM) - FBR

FBR Capital analyst, Vernon Bernardino, reiterated his buy rating and $12 PT on Actinium Pharmaceuticals (NASDAQ: ATNM) ahead of a conference that could act as a platform for the company to release data that could confirm a promising remission rate for AML. No change to numbers, Outperform rating or $12 PT.

Actimab-A (ATNM's alpha particle candidate immunotherapy) is set to emerge at the upcoming annual meeting of the American Society of Hematology, starting on December 5 in Orlando, Florida. Although results are from a small study (n=14), Phase I results (to be presented between 6:00 p.m. and 8:00 p.m. EST, Monday, December 7) should confirm the promising remission rate observed with one cycle of Actimab-A therapy (29%) and to lead to recognition of its potential as a therapeutic option for acute myeloid leukemia (AML), emerging in 2016.

Actimab-A has shown activity against relapsed/ refractory AML and safety at doses up to 3 µCi/kg, which sets it apart, as prior results with other alpha particle–emitting isotopes exhibited doselimiting toxicities (DLTs) at similar emission levels. Recent results with ActimabA showed eight of 11 patients (73%) evaluated after one cycle had bone marrow (BM) blast reductions (mean reduction, 72%; range, 34%–100%), and seven patients (64%) with blast reductions of at least 50%. updated results presented at ASH will show blast reductions of at least 50% with cumulative cycles of Actimab-A, and will point to a potential survival benefit.

The most promising candidates, so far, have demonstrated either lack of efficacy or DLTs. With Actimab-A being the most advanced, we anticipate its continued progress could garner significant partnering interest in 2016, at deal terms that, we estimate, could be worth multiples of $100M, or result in ATNM’s acquisition, similarly to the $2.4B acquisition of the Norway-based biotechnology company Algeta ASA in 2013.

For an analyst ratings summary and ratings history on Actinium Pharma click here. For more ratings news on Actinium Pharma click here.

Shares of Actinium Pharma closed at $2.17 yesterday.

You May Also Be Interested In

• First Advantage to join S&P SmallCap 600, replacing Kennedy-Wilson
• Bernstein SocGen Group Starts Estee Lauder (EL) at Market Perform
• Bernstein SocGen Group Starts Monster Beverage (MNST) at Market Perform